Keywords
How to Cite
Abstract
The aim of the study was to assess efficacy and safety of combined therapy with dacarbazine and melatonin or metformin in comparison with dacarbazine alone in the 1st line of therapy of cutaneous melanoma. Thirty-six patients with disseminated melanoma, therapy naïve, were included between March 2014 and December 2015. Patients received DTIC 1000 mg/m2 in day 1 of 28-day cycle either as monotherapy (group 1) or in combination with melatonin 3 mg PO daily (group 2) or metformin 850 mg 2 times a day PO daily (group 3). Thirty-four patients were randomized (15-in group 1, 8 - in group 2, 13 - in group 3) and received 119 cycles of therapy. Response rate was 11% in groups 1 and 2, and 8,3% - in group 3 (p=0,57). Median time to progression was 52, 79 and 63 days, respectively in the 1st, 2nd and 3rd group (р=0,468). Two patients from the 2nd and 3rd group showed delayed response to therapy. No adverse events of grade 3-4 were seen. Thus, DTIC with melatonin or metformin was well tolerated. No meaningful increase of adverse event incidence was seen. No benefit of either combination was shown in this interim analysis. Delayed responses in melatonin and metformin combination groups were registered. This suggests immunologic effect of both drugs and warrants further study.References
Анисимов В. Н., Айлмазян Э. К., Батурин Д. А. и др. Световой режим, ановуляция и риск злокачественных новообразований женской репродуктивной системы: Механизмы связи и профилактика // Журнал акушерства и женских болезней. - 2003. - Т. LII - № 2 - С. 47-58.
Демидов Л. В., Булавина И. С., Гладков О. А. и др. Практические рекомендации по лекарственному лечению меланомы кожи // Злокачественные опухоли. - 2015. - Т. 4, спецвыпуск - С. 162-170.
Дильман В. М., Берштейн Л. М., Бобров Ю. Ф. и др. Метформин как средство оценки роли эндокриннообменных нарушений в возрастном снижении иммунитета // Физиол. человека. - 1981. - Т. 7. - № 2. - С. 357-359.
Ермаченков Н. А., Гуляев А. В. Анисимов В. Н. Мелатонин и рак толстой кишки: Повышение эффективности стандартного лечения // Вестник Северо-Западного Государственного Медицинского Университета им. И.И. Мечникова. - 2012. - Т. 4. - № 1. - С. 78-83.
Проценко С. А. Дискуссия: «Есть ли место химиотерапии в лечении больных метастатической меланомой?»: Против // М: XIX Российский онкологический конгресс. - 2015.
Eisenhauer E. A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1) // Eur J Cancer. - 2009. - Vol. 45. - I.2. - P. 228-247.
Gonzalez R., Sanchez A., Ferguson J. A. et al. Melatonin therapy of advanced human malignant melanoma // Melanoma Res. - 1991. - Vol.1 -I-4.- P. 237-243.
Lissoni P., Barni S., Tancini G. et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma // Br J Cancer. - 1994. - Vol. 69. - I.1. - P. 196-199/
Lissoni P., Brivio O., Brivio F. et al. Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma // J Pineal Res. - 1996. - Vol. 21. -I.4. - P. 239-242.
Lissoni P., Vaghi M., Ardizzoia A. et al. A phase ii study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (p.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha // In Vivo. - 2002. - Vol. 16. -I.2. - P. 93-96.
MacKenzie M. J., Ernst S., Johnson C.Winquist E. A phase i study of temsirolimus and metformin in advanced solid tumours // Invest New Drugs. - 2012. - Vol. 30. - I.2. - P. 647-652.
Clements A., Gao B., Yeap S. H. et al. Metformin in prostate cancer: Two for the price of one // Ann Oncol. - 2011. - Vol. 22. - I.12. - P. 2556-2560.
Del Barco S., Vazquez-Martin A., Cufi S. et al. Metformin: Multi-faceted protection against cancer // Oncotarget. - 2011. - Vol. 2. - I.12. - P. 896-917.
Institute N. C. Common terminology criteria for adverse events (ctcae).-U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES. - 2010. - 196 p.
Kidd P. Th1/th2 balance: The hypothesis, its limitations, and implications for health and disease // Altern Med Rev. - 2003. - Vol. 8. - I.3. - P. 223-246.
Li D. Metformin as an antitumor agent in cancer prevention and treatment // J Diabetes. -2011. - Vol. 3. - 1.4. - P. 320-327.
Lui P., Cashin R., Machado M. et al. Treatments for metastatic melanoma: Synthesis of evidence from randomized trials //Cancer Treat Rev. - 2007. - Vol. 33. - I.8. - P. 665-680.
Martin-Castillo B., Dorca J., Vazquez-Martin A. et al. Incorporating the antidiabetic drug metformin in her2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: An ongoing clinical-translational research experience at the catalan institute of oncology // Ann Oncol. - 2010. - Vol. 21. - I.1. - P. 187-189.
Miller S. C., Pandi-Perumal S. R., Esquifino A. I. et al. The role of melatonin in immuno-enhancement: Potential application in cancer // Int J Exp Pathol. - 2006. - Vol. 87. - I.2. - P. 81-87.
Oliveras-Ferraros C., Cufi S., Vazquez-Martin A. et al. Metformin rescues cell surface major histocompatibility complex class i (mhc-i) deficiency caused by oncogenic transformation // Cell Cycle. - 2012. - Vol. 11. - 1.5. - P. 865-870.
Peeper D. Metabolism in cellular senescence and therapy // European Journal of Cancer. - 2013. - Vol. 47. - I. Supplement 1. - P.abstr. 353.
Pierotti M. A., Berrino F., Gariboldi M. et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multi-faceted effects // Oncogene. - 2013. - Vol. 32. - I.12. - P. 1475-1487.
Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology // Clin Cancer Res. - 2012. - Vol. 18. - I.1. - P. 40-50.
Pollak M. Metformin and pancreatic cancer: A clue requiring investigation // Clin Cancer Res. - 2012. - Vol. 18. - I. 10. - P. 2723-2725.
Rozengurt E., Sinnett-Smith J.Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and g protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer // Clin Cancer Res. - 2010. - Vol. 16. - I.9. -P. 2505-2511.
Schott S., Bierhaus A., Schuetz F. et al. Therapeutic effects of metformin in breast cancer: Involvement of the immune system? // Cancer Immunol Immunother. - 2011. - Vol. 60. - I.9. - P. 1221-1225.
Seely D., Wu P., Fritz H et al. Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials // Integr Cancer Ther. - 2012. - Vol. 11. - I. 4. - P. 293-303.
Vazquez-Martin A., Oliveras-Ferraros C., Del Barco S. et al. If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials // J Clin Oncol. - 2009. - Vol. 27. - I. 33. - P.e - 207-209; author reply e210.
Wang Y. M., Jin B. Z., Ai F. et al. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials // Cancer Chemother Pharmacol. - 2012. - Vol. 69. - I.5. - P. 1213-1220.
Wysocki P. J.Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: Novel targets and a novel role for metformin // Expert Rev Mol Diagn. - 2010. - Vol. 10. - I.4. - P. 509-519.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...